The MammaPrint assay was originally designed to identify younger breast cancer patients at low risk for distant metastasis, who might consequently be spared systemic treatment.
The Human Genome program and the development of high throughput technologies have set the stage for the latest revolution in medicine, sometimes called the “-omics” revolution.
